On March 2, UK Prime Minister Theresa May delivered a speech on the future of the United Kingdom’s relationship with the European Union, calling for the United Kingdom to remain a member of the European Medicines Agency (EMA), and saying that the United Kingdom could commit to abiding by the rules of the EMA and “making an appropriate financial contribution” to the agency.
On March 2, UK Prime Minister Theresa May delivered a speech on the future of the United Kingdom’s relationship with the European Union, calling for the United Kingdom to remain a member of the European Medicines Agency (EMA), and saying that the United Kingdom could commit to abiding by the rules of the EMA and “making an appropriate financial contribution” to the agency.
“Membership of the [EMA] would mean investment in new innovative medicines continuing in the [United Kingdom], and it would mean these medicines getting to patients faster as firms prioritize larger markets when they start the lengthy process of seeking authorizations,” said May. “But it would also be good for the [European Union], because the UK regulator assesses more new medicines than any other member state. And the [European Union] would continue to access the expertise of the [United Kingdom’s] world-leading universities.”
At the same time, May left open the possibility that the nation might not accept European rules on remaining part of the EMA: “Of course, Parliament would remain ultimately sovereign. It could decide not to accept these rules, but with consequences for our membership of the relevant agency and linked market access rights.”
In response to May’s speech, Bioindustry Association (BIA) CEO Steve Bates said that “It’s good to see [May] articulating the practical dynamics of our industry of the future,” and that “Her language reflects the work that the BIA has undertaken on regulatory cooperation since before the referendum, as well as the desire of patient, [National Health Service] Confederation and European coalitions.”
In delivering the Association of the British Pharmaceutical Industry’s (ABPI) response to the speech, Mike Thompson, ABPI’s chief executive, said, “Every month, 45 million packs of medicines move from the [United Kingdom] to the [European Union]—and 37 million come the other way. That is why the prime minister’s commitment to seek cooperation on medicines regulation would be the best outcome for patients, not just in the [United Kingdom] but across Europe.”
However, cautioned Thompson, cooperation on regulatory matters is only part of the challenge posed by Brexit; ensuring that the supply of medicines remains uninterrupted throughout the United Kingdom and EU territories is critical. Thompson went on to call for establishment of a transition period for the pharmaceutical industry to move to a new framework, and underscored the importance of securing the ability to freely trade and transport medicines across borders, to establish predictable access to funding for scientific research, to form an immigration framework that will allow for skilled professionals from around the world to work in the pharmaceutical industry.
Meanwhile, the EMA is preparing for its relocation from London, United Kingdom, to Amsterdam, the Netherlands, prior for March 29, 2019. Today, the EMA published a new, interactive tracking tool that shows the major milestones of and deliverables associated with the move, with the goal of “giving stakeholders and the public full visibility of the relocation project.”
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.